The estimated Net Worth of Andrew John Hugh Mac Intyre... is at least $13.3 Thousand dollars as of 10 September 2024. Andrew Intyre owns over 4,098 units of Plus Therapeutics stock worth over $13,250 and over the last 5 years Andrew sold PSTV stock worth over $0.
Sign up
Andrew Intyre PSTV stock SEC Form 4 insiders trading
Andrew has made over 7 trades of the Plus Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Andrew bought 4,098 units of PSTV stock worth $5,204 on 10 September 2024.
The largest trade Andrew's ever made was buying 4,902 units of Plus Therapeutics stock on 8 May 2024 worth over $10,000. On average, Andrew trades about 1,769 units every 95 days since 2020. As of 10 September 2024 Andrew still owns at least 9,815 units of Plus Therapeutics stock.
You can see the complete history of Andrew Intyre stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Andrew Intyre's mailing address?
Andrew's mailing address filed with the SEC is C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN, TX, 78756.
Insiders trading at Plus Therapeutics
Over the last 5 years, insiders at Plus Therapeutics have traded over $4,518 worth of Plus Therapeutics stock and bought 251,584 units worth $410,360 . The most active insiders traders include Greg Petersen, Marc H Hedrick, and Richard J Hawkins. On average, Plus Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $8,201. The most recent stock trade was executed by Marc H Hedrick on 10 September 2024, trading 8,000 units of PSTV stock currently worth $9,840.
What does Plus Therapeutics do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
What does Plus Therapeutics's logo look like?
Complete history of Andrew Intyre stock trades at Plus Therapeutics
Plus Therapeutics executives and stock owners
Plus Therapeutics executives and other stock owners filed with the SEC include:
-
Marc Hedrick,
Chief Executive Officer, Director -
Dr. Marc H. Hedrick M.D.,
Pres, CEO & Director -
Steven Kesten,
President and Chief Medical Officer -
Seijiro Shirahama,
President , Asia Pacific -
Annigje van Es-Johansson,
Independent Director -
Greg Petersen,
Independent Director -
Robert Lenk,
Independent Director -
Howard Clowes,
Independent Director -
Mark Marino,
Chief Medical Officer -
Jeremy Hayden,
Vice President - Business Development, General Counsel -
Desiree Smith,
Principal Accounting Officer, Corporate Controller -
Gregory Stein,
Senior Vice President of Clinical Development -
Andrew Sims,
Chief Financial Officer, Vice President - Finance -
Richard Hawkins,
Chairman of the Board -
Dr. Norman D. LaFrance FACNP, FACP, M.D.,
Chief Medical Officer & Sr. VP -
Desiree Smith,
Corp. Controller, Principal Financial & Accounting Officer -
Gary S. Titus CPA,
Advisor -
Russ Havranek M.B.A., M.S.,
VP of Corp. Strategy, New Product Planning & Investor Relations -
Dr. John K. Fraser,
Chief Scientist -
Andrew J. Sims,
VP of Fin. & CFO -
Es Johansson An Van,
-
Norman D. La France,
Chief Medical Officer